Article Text

other Versions

Download PDFPDF
COVID-19 and Behçet’s disease: clinical case series
  1. Gerard Espinosa1,
  2. Olga Araujo2,
  3. Sergi Amaro3,
  4. Marta Bodro4,
  5. Pedro Juan Moreno5,
  6. Reinaldo Moreno6,
  7. Ainoa Ugarte5,
  8. R Cervera7
  1. 1Autoimmune Diseases, University of Barcelona, Barcelona, Catalunya, Spain
  2. 2Autoimmune Diseases, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  3. 3Neurology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  4. 4Infectious Diseases, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  5. 5Internal Medicine, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  6. 6Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  7. 7Autoimmune Diseases, Hospital Clinic, Barcelona, Catalunya, Spain
  1. Correspondence to Dr Gerard Espinosa, Autoimmune Diseases, Hospital Clinic, Barcelona 08036, Spain; gespino{at}clinic.cat

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the study of Monti et al,1 the first rheumatic disease cases with COVID-19. In detail, the authors described the clinical course of COVID-19 in a series of 11 patients with rheumatoid arthritis, one with psoriatic arthritis and one with spondyloarthritis treated with immunosuppressive targeted therapies. Here, we describe the main characteristics of four patients with Behçet’s disease (BD) with COVID-19.

Data on patients with systemic autoimmune diseases with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are currently lacking. Data from the first 110 patients included in the COVID-19 Global Rheumatology Alliance and the European League Against Rheumatism (EULAR)–COVID-19 Database have been recently published.2

Here we describe, to our knowledge, the first single-centre experience of COVID-19 in patients who fulfilled the international criteria for BD,3 including clinical characteristics, antiviral and immunomodulatory treatment, and outcomes. All patients gave informed consent for publishing their clinical data. We used nasopharyngeal swab samples for all diagnoses, amplifying …

View Full Text

Footnotes

  • Twitter @gerardespinosa5

  • Contributors All authors contributed to one or more of the following aspects of the paper: conception, acquisition of data, drafting and revising the article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the Methods section for further details.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; internally peer reviewed.